The past decades have seen a substantial increase in the incidence of pain and morbidity associated with idiopathic osteoarthritis of the knee and hip joints. Analgesics and non-steroidal anti-inflammatory drugs are currently extensively used as palliative treatments, but they are not disease-modifying, do not offer a cure, and have been linked with an increased risk for adverse events. 

Cartilago’s disease-modifying technologies are centered upon peptidyl derivatives that display extraordinary power in stimulating production of new cartilage tissue, as well as the generation of extracellular matrix and collagen, and the endogenous production of hyaluronic acid.